share_log

Eli Lilly and Co | 10-Q: Q3 2024 Earnings Report

Eli Lilly and Co | 10-Q: Q3 2024 Earnings Report

礼来 | 10-Q：2024财年三季报
美股SEC公告 ·  2024/10/30 23:57

Moomoo AI 已提取核心信息

Eli Lilly reported robust Q3 2024 financial results with revenue increasing 20% to $11.4 billion, driven by strong performance of Mounjaro and Zepbound. Net income reached $970.3 million or $1.07 per share, compared to a loss in Q3 2023. U.S. revenue grew 46% to $7.8 billion, while revenue outside U.S. declined 12% to $3.6 billion, primarily due to the sale of the olanzapine portfolio.Mounjaro revenue in the U.S. surged to $2.38 billion, while newly launched Zepbound contributed $1.26 billion. However, sales were impacted by inventory decreases in the wholesaler channel following higher levels in Q2. Verzenio revenue increased 32% to $1.37 billion on strong demand, while Trulicity revenue declined 22% to $1.30 billion due to competitive pressures.The company's gross margin improved to 81.0% from 80.4% year-over-year, benefiting from favorable product mix and higher realized prices. Research and development expenses increased 13% to $2.73 billion, while marketing and administrative expenses rose 16% to $2.10 billion. The company continues to expand manufacturing capacity for incretin medicines to meet growing demand.
Eli Lilly reported robust Q3 2024 financial results with revenue increasing 20% to $11.4 billion, driven by strong performance of Mounjaro and Zepbound. Net income reached $970.3 million or $1.07 per share, compared to a loss in Q3 2023. U.S. revenue grew 46% to $7.8 billion, while revenue outside U.S. declined 12% to $3.6 billion, primarily due to the sale of the olanzapine portfolio.Mounjaro revenue in the U.S. surged to $2.38 billion, while newly launched Zepbound contributed $1.26 billion. However, sales were impacted by inventory decreases in the wholesaler channel following higher levels in Q2. Verzenio revenue increased 32% to $1.37 billion on strong demand, while Trulicity revenue declined 22% to $1.30 billion due to competitive pressures.The company's gross margin improved to 81.0% from 80.4% year-over-year, benefiting from favorable product mix and higher realized prices. Research and development expenses increased 13% to $2.73 billion, while marketing and administrative expenses rose 16% to $2.10 billion. The company continues to expand manufacturing capacity for incretin medicines to meet growing demand.
礼来公司发布了2024年第三季度强劲的财务业绩，营业收入增长20%至114亿美金，主要得益于Mounjaro和Zepbound的良好表现。净利润达到97030万美金，或每股1.07美金，而2023年第三季度则出现亏损。美国的营业收入增长46%至78亿美金，而美国以外的营业收入下降12%至36亿美金，主要由于olanzapine产品组合的销售。Mounjaro在美国的营业收入猛增至23.8亿美金，而新推出的Zepbound贡献了12.6亿美金。然而，销售受到批发渠道库存减少的影响，二季度的库存水平较高。Verzenio的营业收入因需求强劲而增长32%，达到13.7亿美金，而Trulicity的营...展开全部
礼来公司发布了2024年第三季度强劲的财务业绩，营业收入增长20%至114亿美金，主要得益于Mounjaro和Zepbound的良好表现。净利润达到97030万美金，或每股1.07美金，而2023年第三季度则出现亏损。美国的营业收入增长46%至78亿美金，而美国以外的营业收入下降12%至36亿美金，主要由于olanzapine产品组合的销售。Mounjaro在美国的营业收入猛增至23.8亿美金，而新推出的Zepbound贡献了12.6亿美金。然而，销售受到批发渠道库存减少的影响，二季度的库存水平较高。Verzenio的营业收入因需求强劲而增长32%，达到13.7亿美金，而Trulicity的营业收入因竞争压力下降22%，至13亿美金。公司的毛利率从去年的80.4%提高至81.0%，受益于产品组合的改善和更高的实际售价。研发支出增长13%，达到27.3亿美金，而市场营销和管理费用增长16%，达到21亿美金。公司继续扩大制造能力以生产胰高血糖素类药物，以满足日益增长的需求。

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    Medicus Pharma
    MDCX
    -- 3.680
    Scilex Holding
    SCLX
    -- 0.354
    阿玛琳
    AMRN
    -- 0.612
    赛诺菲安万特
    SNY
    -- 54.500
    艾伯维公司
    ABBV
    -- 192.870
    解锁完整榜单
    重估中国资产
    继中国开创性的DeepSeek技术推出之后， 华尔街大行重估对中国市场的投资前景。
    热门讨论
    多家机构看多！中国资产将全面重估：你会如何布局？
    近期，Goldman Sachs、Morgan Stanley、Appaloosa LP等多家机构唱好中国资产。 🎙️讨论： 1. Deepseek引爆中国资产上涨，后市你怎么看？ 2. 多家中国企业1月表现提升，你更看好谁？ 展开
    中国的资产重估引发了讨论：mooer们在买什么？